Ticker League

Operating Income for SELLAS Life Sciences Group (SLS)

Latest filings through · Reported

Metric

TTM

−$31.46M

YoY change

-10.3%

5Y CAGR

—

Peak year (2006)

−$2.40M

Operating Income history chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025

Latest: −$28.27M

Operating Income growth chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025

Latest: -10.3%

Operating Income history table for SELLAS Life Sciences Group (SLS) from 2006 to 2025

  • 2025−$28.27M-10.3%
  • 2024−$31.51M-16.8%
  • 2023−$37.87M-9.7%
  • 2022−$41.95M+65.8%
  • 2021−$25.29M+48.9%
  • 2020−$16.98M-15.3%
  • 2019−$20.04M-36.6%
  • 2018−$31.59M+101.0%
  • 2017−$15.71M-1.7%
  • 2016−$15.99M-53.3%
  • 2015−$34.22M-6.5%
  • 2014−$36.61M+8.2%
  • 2013−$33.84M+59.6%
  • 2012−$21.20M+2.0%
  • 2011−$20.79M+25.0%
  • 2010−$16.63M-5.1%
  • 2009−$17.52M+20.4%
  • 2008−$14.55M+27.5%
  • 2007−$11.41M+374.6%
  • 2006−$2.40M—

Operating Income values are taken from SELLAS Life Sciences Group's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Operating Income at SELLAS Life Sciences Group (SLS)

According to SELLAS Life Sciences Group's latest reported financial statements, the company's current operating income (TTM) is −$31.46M. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

SELLAS Life Sciences Group (SLS) most recent annual operating income stands at −$28.27M (2025) – declined 10.3% year-over-year.

The record annual operating income stands at −$2.40M, reached in 2006; the historical low of −$41.95M was recorded in 2022.

SELLAS Life Sciences Group Operating Income by Year

SELLAS Life Sciences Group Operating Income 2025: −$28.27M

SELLAS Life Sciences Group operating income in 2025 was −$28.27M, declined 10.3% below 2024.

SELLAS Life Sciences Group Operating Income 2024: −$31.51M

2024's operating income for SELLAS Life Sciences Group came in at −$31.51M, declined 16.8% below 2023.

SELLAS Life Sciences Group Operating Income 2023: −$37.87M

SELLAS Life Sciences Group posted operating income of −$37.87M in 2023, declined 9.7% below 2022.

SELLAS Life Sciences Group Operating Income 2022: −$41.95M

In 2022, SELLAS Life Sciences Group reported operating income of −$41.95M, surged 65.8% from 2021. This figure represents the lowest annual value in the available history.

SELLAS Life Sciences Group Operating Income 2021: −$25.29M

SELLAS Life Sciences Group operating income in 2021 was −$25.29M.

See more financial history for SELLAS Life Sciences Group (SLS).

Sector peers by Operating Income

Healthcare peers of SELLAS Life Sciences Group (SLS), ranked by their latest operating income

Frequently asked questions

SELLAS Life Sciences Group (SLS) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview
Capital Return

No dividends paid by this company.